348 related articles for article (PubMed ID: 9760067)
1. Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.
Trepel M; Groscurth P; Malipiero U; Gulbins E; Dichgans J; Weller M
J Neurooncol; 1998 Aug; 39(1):19-32. PubMed ID: 9760067
[TBL] [Abstract][Full Text] [Related]
2. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.
Pohl U; Wagenknecht B; Naumann U; Weller M
Cell Physiol Biochem; 1999; 9(1):29-37. PubMed ID: 10352342
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
Bartussek C; Naumann U; Weller M
Exp Cell Res; 1999 Dec; 253(2):432-9. PubMed ID: 10585266
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of bax in human glioma cell lines.
Vogelbaum MA; Tong JX; Perugu R; Gutmann DH; Rich KM
J Neurosurg; 1999 Sep; 91(3):483-9. PubMed ID: 10470825
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone?
Weller M; Schmidt C; Roth W; Dichgans J
Neurology; 1997 Jun; 48(6):1704-9. PubMed ID: 9191791
[TBL] [Abstract][Full Text] [Related]
6. Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics.
Roth W; Fontana A; Trepel M; Reed JC; Dichgans J; Weller M
Cancer Immunol Immunother; 1997 Mar; 44(1):55-63. PubMed ID: 9111585
[TBL] [Abstract][Full Text] [Related]
7. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Rieger L; Rieger J; Winter S; Streffer J; Esser P; Dichgans J; Meyermann R; Weller M
Acta Neuropathol; 2000 May; 99(5):555-62. PubMed ID: 10805101
[TBL] [Abstract][Full Text] [Related]
8. Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA.
Shou J; Ali-Osman F; Multani AS; Pathak S; Fedi P; Srivenugopal KS
Oncogene; 2002 Jan; 21(6):878-89. PubMed ID: 11840333
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.
Winter S; Weller M
J Pharmacol Exp Ther; 1998 Sep; 286(3):1374-82. PubMed ID: 9732400
[TBL] [Abstract][Full Text] [Related]
11. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
[TBL] [Abstract][Full Text] [Related]
12. The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21(BAX) expression.
Shu HK; Kim MM; Chen P; Furman F; Julin CM; Israel MA
Proc Natl Acad Sci U S A; 1998 Nov; 95(24):14453-8. PubMed ID: 9826721
[TBL] [Abstract][Full Text] [Related]
13. Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells.
Schmidt F; Groscurth P; Kermer M; Dichgans J; Weller M
Acta Neuropathol; 2001 Mar; 101(3):217-24. PubMed ID: 11307620
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lymphoid leukemia cell lines independently of their MDR phenotype.
Lopes EC; Garcia M; Benavides F; Shen J; Conti CJ; Alvarez E; Hajos SE
Leuk Res; 2003 May; 27(5):413-23. PubMed ID: 12620293
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2.
Reber U; Wüllner U; Trepel M; Baumgart J; Seyfried J; Klockgether T; Dichgans J; Weller M
Biochem Pharmacol; 1998 Feb; 55(3):349-59. PubMed ID: 9484802
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation?
Naumann U; Durka S; Weller M
Oncogene; 1998 Sep; 17(12):1567-75. PubMed ID: 9794234
[TBL] [Abstract][Full Text] [Related]
17. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses.
Weller M; Rieger J; Grimmel C; Van Meir EG; De Tribolet N; Krajewski S; Reed JC; von Deimling A; Dichgans J
Int J Cancer; 1998 Dec; 79(6):640-4. PubMed ID: 9842975
[TBL] [Abstract][Full Text] [Related]
18. High linear energy transfer carbon radiation effectively kills cultured glioma cells with either mutant or wild-type p53.
Iwadate Y; Mizoe J; Osaka Y; Yamaura A; Tsujii H
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):803-8. PubMed ID: 11395250
[TBL] [Abstract][Full Text] [Related]
19. Failure of taxol-based combination chemotherapy for malignant glioma cannot be overcome by G2/M checkpoint abrogators or altering the p53 status.
Borbé R; Rieger J; Weller M
Cancer Chemother Pharmacol; 1999; 44(3):217-27. PubMed ID: 10453723
[TBL] [Abstract][Full Text] [Related]
20. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis.
Wick W; Furnari FB; Naumann U; Cavenee WK; Weller M
Oncogene; 1999 Jul; 18(27):3936-43. PubMed ID: 10435616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
